Comparison on efficacy and safety of pitavastatin calcium and atorvastatin calcium in the clinical treatment of coronary heart disease
Objective To study and compare the efficacy and safety of pitavastatin calcium and atorvastatin calcium in the clinical treatment of coronary heart disease.Methods 80 patients with coronary heart disease were divided into a control group and a study group according to random numerical table,with 40 patients in each group.The control group was treated with atorvastatin calcium,while the study group was treated with pitavastatin calcium.Comparison was made on the treatment effect,occurrence of adverse reactions,blood lipid indicators(total cholesterol,triglyceride,low-density lipoprotein cholesterol),myocardial injury indicators(troponin I,creatine kinase isoenzyme,lactate dehydrogenase),hemorheological indicators(whole-blood high-shear viscosity,whole-blood low-shear viscosity,plasma viscosity,hematocrit),and quality of life scores between and within the two groups.Results The total effective rate of 97.50%in the study group was higher than 82.50%in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the total cholesterol,triglyceride and low-density lipoprotein cholesterol in both groups were lower than those before treatment;in the study group,the total cholesterol was(4.37±0.74)mmol/L,the triglyceride was(1.22±0.33)mmol/L,the low-density lipoprotein cholesterol was(2.96±0.37)mmol/L,which were lower than(5.24±0.87),(1.61±0.40)and(3.35±0.39)mmol/L in the control group(P<0.05).After treatment,the troponin I,creatine kinase isoenzyme and lactate dehydrogenase in both groups were lower than those before treatment;in the study group,the troponin I was(0.08±0.02)μg/L,the creatine kinase isoenzyme was(16.20±2.39)U/L,and the lactate dehydrogenase was(235.59±10.62)U/L,which were lower than(0.15±0.01)μg/L,(23.39±2.94)U/L,and(250.16±12.45)U/L in the control group(P<0.05).After treatment,the whole-blood high-shear viscosity,whole-blood low-shear viscosity,plasma viscosity,and hematocrit in both groups were lower than those before treatment;in the study group,the whole-blood high-shear viscosity was(4.50±0.43)mPa·s,the whole-blood low-shear viscosity was(10.75±0.69)mPa·s,the plasma viscosity was(1.68±0.31)mPa·s,and the hematocrit was(33.27±2.08)%,which were all lower than(5.01±0.49)mPa·s,(11.60±0.73)mPa·s,(2.07±0.35)mPa·s,and(35.59±2.04)%in the control group(P<0.05).After treatment,the scores of physiology,psychology,environment and social relations in both groups were higher than those before treatment;the scores of physiology,psychology,environment and social relations were(89.75±6.48),(89.07±6.02),(90.14±6.15),and(89.96±6.27)points in the study group,which were higher than(82.93±6.85),(82.40±6.13),(83.27±6.30),and(83.14±6.54)points in the control group(P<0.05).Conclusion For patients with coronary heart disease,the effect of pitavastatin calcium is superior to atorvastatin calcium.Pitavastatin calcium can more effectively improve the patient's lipid metabolism and hemorheology,reduce myocardial damage,and is beneficial for improving their quality of life.Moreover,the risk of adverse reactions between pitavastatin calcium and atorvastatin calcium is comparable,so it has good drug safety.
NETL
NSTL
万方数据
